[1] |
SAEEDI P, PETERSOHN I, SALPEA P,et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas,9th edition[J]. Diabetes Res Clin Pract,2019,157:107843.DOI:10.1016/j.diabres.2019.107843.
|
[2] |
American Diabetes Association.11.microvascular complications and foot care:standards of medical care in diabetes—2020[J]. Diabetes Care,2020,43():S135-151.DOI:10.2337/dc20-S011.
|
[3] |
ALDEMIR O, TURGUT F, GOKCE C.The association between methylation levels of targeted genes and albuminuria in patients with early diabetic kidney disease[J]. Ren Fail,2017,39(1):597-601.DOI:10.1080/0886022X.2017.1358180.
|
[4] |
LUK A O Y, HUI E M T, SIN M C,et al. Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes:the Hong Kong diabetes database[J]. Diabetes Care,2017,40(7):928-935.DOI:10.2337/dc16-2354.
|
[5] |
AFKARIAN M, ZELNICK L R, HALL Y N,et al. Clinical manifestations of kidney disease among US adults with diabetes,1988—2014[J]. JAMA,2016,316(6):602-610.DOI:10.1001/jama.2016.10924.
|
[6] |
LIU Z H.Nephrology in China[J]. Nat Rev Nephrol,2013,9(9):523-528.DOI:10.1038/nrneph.2013.146.
|
[7] |
MOGENSEN C E, CHRISTENSEN C K, VITTINGHUS E.The stages in diabetic renal disease.With emphasis on the stage of incipient diabetic nephropathy[J]. Diabetes,1983,32():64-78.DOI:10.2337/diab.32.2.s64.
|
[8] |
American Diabetes Association.15.diabetes advocacy:standards of medical care in diabetes—2018[J]. Diabetes Care,2018,41():S152-153.DOI:10.2337/dc18-S015.
|
[9] |
ALBERTI K G, ZIMMET P Z.Definition,diagnosis and classification of diabetes mellitus and its complications.Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med,1998,15(7):539-553.DOI:10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S.
|
[10] |
中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
|
[11] |
ZHANG Z H, ZHANG H Y, KHANAL M K.Development of scoring system for risk stratification in clinical medicine:a step-by-step tutorial[J]. Ann Transl Med,2017,5(21):436.DOI:10.21037/atm.2017.08.22.
|
[12] |
BALACHANDRAN V P, GONEN M, SMITH J J,et al. Nomograms in oncology:more than meets the eye[J]. Lancet Oncol,2015,16(4):e173-180.DOI:10.1016/S1470-2045(14)71116-7.
|
[13] |
WANG H J, ZHANG L, LIU Z,et al. Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population:development and assessment of a new predictive nomogram[J]. Patient Prefer Adherence,2018,12:1757-1765.DOI:10.2147/PPA.S159293.
|
[14] |
WEI L, CHAMPMAN S, LI X M,et al. Beliefs about medicines and non-adherence in patients with stroke,diabetes mellitus and rheumatoid arthritis:a cross-sectional study in China[J]. BMJ Open,2017,7(10):e017293.DOI:10.1136/bmjopen-2017-017293.
|
[15] |
JIANG S M, FANG J Y, YU T,et al. Novel model predicts diabetic nephropathy in type 2 diabetes[J]. Am J Nephrol,2020,51(2):130-138.DOI:10.1159/000505145.
|
[16] |
ADLER A I, STEVENS R J, MANLEY S E,et al. Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS 64)[J]. Kidney Int,2003,63(1):225-232.DOI:10.1046/j.1523-1755.2003.00712.x.
|
[17] |
MOGENSEN C E, KEANE W F, BENNETT P H,et al. Prevention of diabetic renal disease with special reference to microalbuminuria[J]. Lancet,1995,346(8982):1080-1084.DOI:10.1016/s0140-6736(95)91747-0.
|
[18] |
LEEHEY D J, ZHANG J H, EMANUELE N V,et al. BP and renal outcomes in diabetic kidney disease:the veterans affairs nephropathy in diabetes trial[J]. Clin J Am Soc Nephrol,2015,10(12):2159-2169.DOI:10.2215/CJN.02850315.
|
[19] |
HOLMAN R R, PAUL S K, BETHEL M A,et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Engl J Med,2008,359(15):1577-1589.DOI:10.1056/NEJMoa0806470.
|
[20] |
HOLMAN R R, PAUL S K, BETHEL M A,et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes[J]. N Engl J Med,2008,359(15):1565-1576.DOI:10.1056/NEJMoa0806359.
|
[21] |
HU Y H, SHI R, MO R H,et al. Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators:a retrospective study[J]. Aging (Albany NY),2020,12(11):10317-10336.DOI:10.18632/aging.103259.
|
[22] |
ISMAIL-BEIGI F, CRAVEN T, BANERJI M A,et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes:an analysis of the ACCORD randomised trial[J]. Lancet,2010,376(9739):419-430.DOI:10.1016/S0140-6736(10)60576-4.
|
[23] |
RUSSO G T, DE COSMO S, VIAZZI F,et al. Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes:the AMD annals initiative[J]. Diabetes Care,2016,39(12):2278-2287.DOI:10.2337/dc16-1246.
|
[24] |
YANG H, YOUNG D, GAO J,et al. Are blood lipids associated with microvascular complications among type 2 diabetes mellitus patients? A cross-sectional study in Shanghai,China[J]. Lipids Health Dis,2019,18(1):18.DOI:10.1186/s12944-019-0970-2.
|
[25] |
KHAN S H, SOBIA F, NIAZI N K,et al. Metabolic clustering of risk factors:evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance[J]. Diabetol Metab Syndr,2018,10:74.DOI:10.1186/s13098-018-0376-8.
|
[26] |
CHENG Y Q, SHANG J, LIU D,et al. Development and validation of a predictive model for the progression of diabetic kidney disease to kidney failure[J]. Ren Fail,2020,42(1):550-559.DOI:10.1080/0886022X.2020.1772294.
|
[27] |
QIU X L, LIU C Y, YE Y Q,et al. The diagnostic value of serum creatinine and cystatin C in evaluating glomerular filtration rate in patients with chronic kidney disease:a systematic literature review and meta-analysis[J]. Oncotarget,2017,8(42):72985-72999.DOI:10.18632/oncotarget.20271.
|
[28] |
ZENG X F, LU D X, LI J M,et al. Performance of urinary neutrophil gelatinase-associated lipocalin,clusterin,and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria:a consecutive cohort study[J]. BMC Nephrol,2017,18(1):233.DOI:10.1186/s12882-017-0620-8.
|
[29] |
PAUL S, ALI A, KATARE R.Molecular complexities underlying the vascular complications of diabetes mellitus -a comprehensive review[J]. J Diabetes Complications,2020,34(8):107613.DOI:10.1016/j.jdiacomp.2020.107613.
|
[30] |
PEARCE I, SIMÓ R, LÖVESTAM-ADRIAN M,et al. Association between diabetic eye disease and other complications of diabetes:Implications for care.A systematic review[J]. Diabetes Obes Metab,2019,21(3):467-478.DOI:10.1111/dom.13550.
|